OBJECTIVE: To evaluate the role of (68)Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-Octreotide ((68)Ga-DOTA-NOC) whole body positron emission tomography-computed tomography (PET-CT) as a functional imaging approach for phaeochromocytoma and paraganglioma. METHODS: Thirty-five unrelated patients (Median age-34.4 years; range: 15-71) were evaluated in this prospective study. PET-CT was performed after injection of 132-222 MBq of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (standardised uptake value-SUVmax). In addition we compared the findings with (131)I Metaiodobenzylguanidine (MIBG) scintigraphy, which was available for 25 patients. Histopathology and/or conventional imaging with biochemical markers were taken as the reference standard. RESULTS: 44 lesions were detected on (68)Ga-DOTA-NOC PET-CT imaging with an additional detection of 12 lesions not previously known, leading to a change in management of 6 patients. Sensitivity, specificity and accuracy were 100%, 85.7%, and 97.1% on a per patient basis and 100%, 85.7% and 98% on per lesion basis, respectively.(131)I MIBG scintigraphy was concordant with (68)Ga-DOTA-NOC PET-CT in 16 patients and false negative in 9 patients. CONCLUSION: (68)Ga-DOTA-NOC PET-CT is highly sensitive and specific for the detection of phaeochromoctyomas and paragangliomas. It seems better than (131)I MIBG scintigraphy for this purpose. KEY POINTS: • ( 68 ) Ga-DOTA-NOC PET-CT seems useful in patients with phaeochromocytoma and paraganglioma. • This prospective single centre study showed that it has high diagnostic accuracy. • (68) Ga-DOTA-NOC PET-CT seems superior to (131) I-MIBG in these patients.
OBJECTIVE: To evaluate the role of (68)Ga-labelled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-Octreotide ((68)Ga-DOTA-NOC) whole body positron emission tomography-computed tomography (PET-CT) as a functional imaging approach for phaeochromocytoma and paraganglioma. METHODS: Thirty-five unrelated patients (Median age-34.4 years; range: 15-71) were evaluated in this prospective study. PET-CT was performed after injection of 132-222 MBq of (68)Ga-DOTA-NOC. Images were evaluated by two experienced nuclear medicine physicians both qualitatively as well as quantitatively (standardised uptake value-SUVmax). In addition we compared the findings with (131)I Metaiodobenzylguanidine (MIBG) scintigraphy, which was available for 25 patients. Histopathology and/or conventional imaging with biochemical markers were taken as the reference standard. RESULTS: 44 lesions were detected on (68)Ga-DOTA-NOC PET-CT imaging with an additional detection of 12 lesions not previously known, leading to a change in management of 6 patients. Sensitivity, specificity and accuracy were 100%, 85.7%, and 97.1% on a per patient basis and 100%, 85.7% and 98% on per lesion basis, respectively.(131)I MIBG scintigraphy was concordant with (68)Ga-DOTA-NOC PET-CT in 16 patients and false negative in 9 patients. CONCLUSION: (68)Ga-DOTA-NOC PET-CT is highly sensitive and specific for the detection of phaeochromoctyomas and paragangliomas. It seems better than (131)I MIBG scintigraphy for this purpose. KEY POINTS: • ( 68 ) Ga-DOTA-NOC PET-CT seems useful in patients with phaeochromocytoma and paraganglioma. • This prospective single centre study showed that it has high diagnostic accuracy. • (68) Ga-DOTA-NOC PET-CT seems superior to (131) I-MIBG in these patients.
Authors: E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: G Kaltsas; M Korbonits; E Heintz; J J Mukherjee; P J Jenkins; S L Chew; R Reznek; J P Monson; G M Besser; R Foley; K E Britton; A B Grossman Journal: J Clin Endocrinol Metab Date: 2001-02 Impact factor: 5.958
Authors: B Eriksson; H Orlefors; K Oberg; A Sundin; M Bergström; B Långström Journal: Best Pract Res Clin Endocrinol Metab Date: 2005-06 Impact factor: 4.690
Authors: H P Neumann; D P Berger; G Sigmund; U Blum; D Schmidt; R J Parmer; B Volk; G Kirste Journal: N Engl J Med Date: 1993-11-18 Impact factor: 91.245
Authors: Ingo Janssen; Clara C Chen; Zhenping Zhuang; Corina M Millo; Katherine I Wolf; Alexander Ling; Frank I Lin; Karen T Adams; Peter Herscovitch; Richard A Feelders; Antonio T Fojo; David Taieb; Electron Kebebew; Karel Pacak Journal: J Nucl Med Date: 2017-03-23 Impact factor: 10.057
Authors: Ingrid J G Burvenich; Sagun Parakh; Adam C Parslow; Sze Ting Lee; Hui K Gan; Andrew M Scott Journal: AAPS J Date: 2018-03-08 Impact factor: 4.009
Authors: Ingo Janssen; Clara C Chen; Corina M Millo; Alexander Ling; David Taieb; Frank I Lin; Karen T Adams; Katherine I Wolf; Peter Herscovitch; Antonio T Fojo; Inga Buchmann; Electron Kebebew; Karel Pacak Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-21 Impact factor: 9.236